Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

Innodata sees explosive growth with LLM training data demand. See why INOD stock’s future depends on automation and continued ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A decade after the first introduction of angiography-derived fractional flow reserve (FFR), we are now entering an era in which simplified image-derived solutions could replace invasive assessment ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link ...

What causes heart disease? Heart disease is a broad reference to multiple heart conditions. The most common is coronary ...

Over 80% of these fatalities result from heart attacks and strokes. December is notorious for being the biggest month for heart attacks, with one of the most dangerous being the widowmaker heart ...

While more people than ever are running marathons in the U.S., the risk of dying from a heart attack during a run has fallen ...

New research presented at the EHRA 2025, a scientific congress of the European Society of Cardiology, shows that the presence ...